Note to the businessman

Note to the businessman

Venture Market Navigator

The PwC Center for Technology and Innovation together with RVC present the fifth annual review of the Russian venture industry "MoneyTreeTM: Navigator of the Venture Market" for 2015.

24.03.2016

Note to the businessman

Overview of the private equity and venture capital investment market for 9 months of 2015

To prepare this book, experts of the Russian Venture Investment Association conducted a large-scale study of the direct and venture investment market.

28.01.2016

Note to the businessman

Money from Genes

Just three years after discovering its potential in gene editing, the new CRISPR technique has become the hottest and most controversial in the field of genomics. And now it's more than science: it's big business.

26.01.2016

Note to the businessman

New opportunities for Russian startups

Due to the crisis, the number and volume of transactions on the Russian market have decreased, and in conditions of reduced liquidity, businessmen from real sectors are increasingly interested in venture capital. In 2015, 13 new venture funds were launched in Russia.

16.12.2015

Note to the businessman

The Russian market of direct and venture investments fell by almost 10%

The review was prepared according to the methodology of collecting and analyzing the main parameters of the activities of Russian venture funds, which ensures comparability of the results of research on the Russian market of direct and venture investments.

15.12.2015

Note to the businessman

Together against aging

The first "merger and acquisition" in the field of bioinformatics of aging: Insilico Medicine and InSilicoScreen merge in order to take the study of aging to a new level.

15.12.2015

Note to the businessman

Immunotherapeutic drugs: growth forecast

According to the forecast of the research company "MarketsandMarkets", the average annual growth rate of the global market of drugs for immunotherapy in the near future will be 12.8% and by 2020 will reach $73.5 billion.

03.12.2015

Note to the businessman

RVC invested in the development of drugs for blindness

RetroSense Terapeutics is a private biopharmaceutical company developing a drug for the treatment of retinitis pigmentosa and age–related macular degeneration.

26.11.2015

Note to the businessman

Commercial medicine is increasingly attracting investors

At the end of November 2015, a new private medical center "Clinical Hospital on Yauza" will open in Moscow. Its main investor was Dmitry Vasiliev, First Deputy General Director of a large IT company Krok.

29.10.2015

Note to the businessman

Venture Market statistics

The volume of capital in the market has not changed much, which, taking into account the departure of a number of major foreign players from the industry, suggests that the industry of Russian – in the long term – innovations remains attractive and interesting for investors.

15.10.2015

Note to the businessman

Northwest becomes an outpost of biopharma development

Biopharmaceuticals and biomedicine are considered to be the most attractive segment of the biotechnological market for investment.

14.10.2015

Note to the businessman

Innovations in biotech are not a luxury, but a means of survival

The examples of Celgene, Genzyme and Monsanto show how innovative strategies can pay off.

12.10.2015

Note to the businessman

The pharmaceutical extortionist made excuses for a long time and tongue-tied, and lied all the time (With)

About how mr. Shkreli acquired the rights to the drug daraprim and immediately raised the price for it 55 times and about the reaction of American society to this, from doctors and their patients to the presidential candidate.

05.10.2015

Note to the businessman

What to choose in the biotech market?

The director of the analytical department of the IC "Golden Hills – Capital AM" advises not to acquire firms of a low degree of reliability, but in time-tested securities of companies with a total value of shares over $ 100 billion.

02.10.2015

Note to the businessman

Pharmaceutical businessmen are far from oilmen, but still…

The list of 500 leaders of Russian business includes 23 companies operating in the pharmaceutical market, 10 of them are pharmaceutical distributors.

25.09.2015

Note to the businessman

About greedy merchants

Hillary Clinton in her microblog on Twitter promised to present a plan to combat the increase in drug prices. After this statement, the index of biotech companies traded on the Nasdaq stock exchange fell by 4.7%.

23.09.2015

Note to the businessman

Biopharmaceuticals on the rise

The biopharmaceutical funding boom continues. In the first half of 2015, investors invested more money in these areas than in the whole of 2013.

16.09.2015

Note to the businessman

Biopharmaceutics: a premonition of a bubble

Last year, the shares of companies at the preliminary testing stage or in Phase 1 on the first day of trading grew by an average of 29%. The situation is somewhat reminiscent of the famous dot-com bubble, when stocks soared by 50-70% on the first day of trading

14.09.2015

Note to the businessman

Import substitution in a crisis

No one can answer the question of how soon the domestic pharmaceutical industry will be able to produce a sufficient number of medicines of the right quality.

09.09.2015

Note to the businessman

Bioengineering: sales growth forecast

The volume of sales of medicines of biological origin containing an analogue of the active substance of the original drug on the world market will increase from $20 billion, projected by the end of 2015, to $55 billion by 2020.

08.07.2015